The stock of Insys Therapeutics Inc (NASDAQ:INSY) is a huge mover today! About 428,610 shares traded hands. Insys Therapeutics Inc (NASDAQ:INSY) has declined 2.02% since April 14, 2016 and is downtrending. It has underperformed by 6.70% the S&P500.
The move comes after 8 months negative chart setup for the $897.05 million company. It was reported on Nov, 16 by Barchart.com. We have $11.98 PT which if reached, will make NASDAQ:INSY worth $62.79M less.
Insys Therapeutics Inc (NASDAQ:INSY) Ratings Coverage
Out of 4 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Insys Therapeutics has been the topic of 9 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Thursday, August 4 by Jefferies. As per Monday, October 10, the company rating was maintained by Jefferies. The company was initiated on Thursday, April 14 by Janney Capital. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. The stock of Insys Therapeutics Inc (NASDAQ:INSY) earned “Buy” rating by Zacks on Friday, August 14. RBC Capital Markets maintained the shares of INSY in a report on Thursday, September 22 with “Outperform” rating. The stock has “Hold” rating given by Oppenheimer on Tuesday, August 4. As per Tuesday, April 12, the company rating was maintained by Jefferies. The firm has “Buy” rating given on Wednesday, February 24 by Jefferies.
According to Zacks Investment Research, “Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona.”
Insitutional Activity: The institutional sentiment decreased to 0.7 in 2016 Q2. Its down 0.36, from 1.06 in 2016Q1. The ratio dropped, as 22 funds sold all Insys Therapeutics Inc shares owned while 42 reduced positions. 13 funds bought stakes while 32 increased positions. They now own 31.30 million shares or 9.76% less from 34.69 million shares in 2016Q1.
Commerzbank Aktiengesellschaft Fi accumulated 31,941 shares or 0% of the stock. Blackrock Gru Limited accumulated 0% or 93,015 shares. The New York-based State Common Retirement Fund has invested 0% in Insys Therapeutics Inc (NASDAQ:INSY). Legal & General Grp Public Limited Liability Corp holds 6,247 shares or 0% of its portfolio. Eqis Capital Inc has 94,774 shares for 0.08% of their US portfolio. The Israel-based Sphera Funds Mngmt Limited has invested 0.06% in Insys Therapeutics Inc (NASDAQ:INSY). Moreover, Royal Savings Bank Of Canada has 0% invested in Insys Therapeutics Inc (NASDAQ:INSY) for 2,283 shares. Moreover, Acadian Asset Mgmt Limited Com has 0% invested in Insys Therapeutics Inc (NASDAQ:INSY) for 350 shares. 12 West Mgmt Lp last reported 1.3% of its portfolio in the stock. Alliancebernstein Lp holds 0% or 61,120 shares in its portfolio. Bridgeway Capital, a Texas-based fund reported 13,000 shares. Citigroup holds 18,511 shares or 0% of its portfolio. Commercial Bank Of America Corp De accumulated 13,125 shares or 0% of the stock. Geode Ltd Llc has invested 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY). The New York-based Gotham Asset Ltd Limited Liability Company has invested 0.15% in Insys Therapeutics Inc (NASDAQ:INSY).
Insider Transactions: Since June 6, 2016, the stock had 2 insider buys, and 4 selling transactions for $704,930 net activity. $270,300 worth of Insys Therapeutics Inc (NASDAQ:INSY) shares were sold by STANLEY THEODORE H. The insider MEYER STEVEN J bought $107,489. $276,900 worth of Insys Therapeutics Inc (NASDAQ:INSY) was sold by FOURTEAU PATRICK on Thursday, August 11. $105,853 worth of Insys Therapeutics Inc (NASDAQ:INSY) shares were bought by JOHN N KAPOOR TRUST DATED SEPTEMBER 20 1989. $110,752 worth of Insys Therapeutics Inc (NASDAQ:INSY) was sold by BRENNAN DANIEL on Tuesday, August 9.
Another recent and important Insys Therapeutics Inc (NASDAQ:INSY) news was published by Forbes.com which published an article titled: “Insys Therapeutics Pops On Earnings Beat, But Revenues Plunge” on November 03, 2016.
INSY Company Profile
Insys Therapeutics, Inc., incorporated on June 15, 1990, is a commercial-stage specialty pharmaceutical company. The Firm develops and commercializes supportive care products. Subsys is the Company’s marketed product. Subsys is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and is a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Firm markets Subsys through its field sales force focused on supportive care physicians in the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.